Immunocytokines: a review of molecules in clinical development for cancer therapy

References

• KirkwoodJMButterfieldLHTarhiniAAZarourHKalinskiPFerroneSImmunotherapy of cancer in 2012CA Cancer J Clin201262530933522576456
   PubMed Web of Science ®Google Scholar
• AokiTTashiroKMiyatakeSExpression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivoProc Natl Acad Sci U S A1992899385038541570303
   PubMed Web of Science ®Google Scholar
• BarkerSEGrosseSMSiapatiEKImmunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12Br J Cancer200797221021717595664
   PubMed Web of Science ®Google Scholar
• JackamanCBundellCSKinnearBFIL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2J Immunol2003171105051506314607902
   PubMed Web of Science ®Google Scholar
• KoshitaYLuYFujiiSEfficacy of TNF-alpha gene-transduced tumor cells in treatment of established in vivo tumorInt J Cancer19956311301357558441
   PubMed Web of Science ®Google Scholar
• MillerPWSharmaSStolinaMIntratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradicationHum Gene Ther2000111536510646639
   PubMed Web of Science ®Google Scholar
• HalinCRondiniSNilssonFEnhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculatureNat Biotechnol200220326426911875427
   PubMed Web of Science ®Google Scholar
• GilliesSDImmunocytokines: a novel approach to cancer immune therapyLustgartenJCuiYLiSTargeted Cancer Immune Therapy2009241256
   Google Scholar
• GutbrodtKNeriDImmunocytokinesAntibodies2012117087
   Google Scholar
• PascheNNeriDImmunocytokines: a novel class of potent armed antibodiesDrug Discov Today20121711–1258359022289353
   PubMed Web of Science ®Google Scholar
• KontermannREAntibody-cytokine fusion proteinsArch Biochem Biophys2012526219420522445675
   PubMed Web of Science ®Google Scholar
• NiesnerUHalinCLozziLQuantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptidesBioconjug Chem200213472973612121127
   PubMed Web of Science ®Google Scholar
• MelkkoSHalinCBorsiLZardiLNeriDAn antibody-calmodulin fusion protein reveals a functional dependence between macromolecular isoelectric point and tumor targeting performanceInt J Radiat Oncol Biol Phys20025451485149012459375
   PubMed Web of Science ®Google Scholar
• HalinCNiesnerUVillaniMEZardiLNeriDTumor-targeting properties of antibody-vascular endothelial growth factor fusion proteinsInt J Cancer2002102210911612385005
   PubMed Web of Science ®Google Scholar
• HemmerleTWulhfardSNeriDA critical evaluation of the tumor-targeting properties of bispecific antibodies based on quantitative biodistribution dataProtein Eng Des Sel2012251285185422972762
   PubMed Web of Science ®Google Scholar
• GafnerVTrachselENeriDAn engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting propertiesInt J Cancer200611992205221216823838
   PubMed Web of Science ®Google Scholar
• EbbinghausCRoncaRKasparMEngineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapyInt J Cancer2005116230431315800913
   PubMed Web of Science ®Google Scholar
• KuoTTAvesonVGNeonatal Fc receptor and IgG-based therapeuticsMAbs20113542243022048693
   PubMed Web of Science ®Google Scholar
• WoofJMBurtonDRHuman antibody-Fc receptor interactions illuminated by crystal structuresNat Rev Immunol200442899915040582
   PubMed Web of Science ®Google Scholar
• GilliesSDLanYLoKMSuperMWesolowskiJImproving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptorsCancer Res19995992159216610232603
   PubMed Web of Science ®Google Scholar
• GilliesSDLoKMBurgerCLanYDahlTWongWKImproved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysisClin Cancer Res20028121021611801561
   PubMed Web of Science ®Google Scholar
• JainRKBaxterLTMechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressureCancer Res19884824 Pt 1702270323191477
   PubMed Web of Science ®Google Scholar
• YokotaTMilenicDEWhitlowMSchlomJRapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin formsCancer Res19925212340234081596900
   PubMed Web of Science ®Google Scholar
• GraffCPWittrupKDTheoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retentionCancer Res20036361288129612649189
   PubMed Web of Science ®Google Scholar
• MilenicDEYokotaTFilpulaDRConstruction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49Cancer Res19915123 Pt 1636363711933899
   PubMed Web of Science ®Google Scholar
• BorsiLBalzaEBestagnoMSelective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectinInt J Cancer20021021758512353237
   PubMed Web of Science ®Google Scholar
• HolligerPHudsonPJEngineered antibody fragments and the rise of single domainsNat Biotechnol20052391126113616151406
   PubMed Web of Science ®Google Scholar
• WuAMSenterPDArming antibodies: prospects and challenges for immunoconjugatesNat Biotechnol20052391137114616151407
   PubMed Web of Science ®Google Scholar
• NaramuraMGilliesSDMendelsohnJReisfeldRAMuellerBMMechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cellsImmunol Lett199339191998144194
   PubMed Web of Science ®Google Scholar
• AldersonKLSondelPMClinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicityJ Biomed Biotechnol2011201137912321660134
   PubMedGoogle Scholar
• DoraiHMuellerBMReisfeldRAGilliesSDAglycosylated chimeric mouse/human IgG1 antibody retains some effector functionHybridoma19911022112171874515
   PubMedGoogle Scholar
• BaeuerlePReinhardtCBispecific T-cell engaging antibodies for cancer therapyCancer Res200969124941494419509221
   PubMed Web of Science ®Google Scholar
• LustgartenJMarksJShermanLARedirecting effector T cells through their IL-2 receptorsJ Immunol199916213593659886407
   PubMed Web of Science ®Google Scholar
• GubbelsJAGadbawBBuhtoiarovINAb-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interfaceCancer Immunol Immunother201160121789180021792658
   PubMed Web of Science ®Google Scholar
• BuhtoiarovINNealZCGanJDifferential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targetingJ Leukoc Biol201189462563821248148
   PubMed Web of Science ®Google Scholar
• ChangHRCordon-CardoCHoughtonANCheungNKBrennanMFExpression of disialogangliosides GD2 and GD3 on human soft tissue sarcomasCancer19927036336381623478
   PubMed Web of Science ®Google Scholar
• SvennerholmLBostromKFredmanPGangliosides and allied glycosphingolipids in human peripheral nerve and spinal cordBiochim Biophys Acta1994121421151237918590
   PubMed Web of Science ®Google Scholar
• MujooKChereshDAYangHMReisfeldRADisialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growthCancer Res1987474109811043100030
   PubMed Web of Science ®Google Scholar
• YamaneBHHankJAAlbertiniMRSondelPMThe development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastomaExpert Opin Investig Drugs20091879911000
   PubMed Web of Science ®Google Scholar
• CheungNKSaarinenUMNeelyJELandmeierBDonovanDCocciaPFMonoclonal antibodies to a glycolipid antigen on human neuroblastoma cellsCancer Res1985456264226492580625
   PubMed Web of Science ®Google Scholar
• ModakSGeraldWCheungNKDisialoganglioside GD2 and a novel tumor antigen: potential targets for immunotherapy of desmoplastic small round cell tumorMed Pediatr Oncol200239654755112376975
   PubMedGoogle Scholar
• HanahanDWeinbergRAHallmarks of cancer: the next generationCell2011144564667421376230
   PubMed Web of Science ®Google Scholar
• ZardiLCarnemollaBSiriATransformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exonEMBO J198768233723422822387
   PubMed Web of Science ®Google Scholar
• NeriDBicknellRTumour vascular targetingNat Rev Cancer20055643644615928674
   PubMed Web of Science ®Google Scholar
• CarnemollaBBalzaESiriAA tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursorsJ Cell Biol19891083113911482646306
   PubMed Web of Science ®Google Scholar
• KaczmarekJCastellaniPNicoloGSpinaBAllemanniGZardiLDistribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissuesInt J Cancer199459111167927891
   PubMed Web of Science ®Google Scholar
• CastellaniPVialeGDorcarattoAThe fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesisInt J Cancer19945956126187525495
   PubMed Web of Science ®Google Scholar
• CastellaniPBorsiLCarnemollaBDifferentiation between high-and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectinAm J Pathol200216151695170012414516
   PubMed Web of Science ®Google Scholar
• ListTNeriDBiodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor siteMAbs20124677578323032949
   PubMed Web of Science ®Google Scholar
• VitiFTarliLGiovannoniLZardiLNeriDIncreased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesisCancer Res19995923473529927045
   PubMed Web of Science ®Google Scholar
• TarliLBalzaEVitiFA high-affinity human antibody that targets tumoral blood vesselsBlood199994119219810381513
   PubMed Web of Science ®Google Scholar
• DemartisSTarliLBorsiLZardiLNeriDSelective targeting of tumour neovasculature by a radiohalogenated human antibody fragment specific for the ED-B domain of fibronectinEur J Nucl Med200128453453911357506
   PubMedGoogle Scholar
• SantimariaMMoscatelliGVialeGLImmunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancerClin Cancer Res20039257157912576420
   PubMed Web of Science ®Google Scholar
• BorsiLCarnemollaBNicoloGSpinaBTanaraGZardiLExpression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissuesInt J Cancer19925256886921385335
   PubMed Web of Science ®Google Scholar
• CarnemollaBCastellaniPPonassiMIdentification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibodyAm J Pathol199915451345135210329587
   PubMed Web of Science ®Google Scholar
• SchwagerKVillaARosliCNeriDRosli-KhabasMMoserGA comparative immunofuorescence analysis of three clinical-stage antibodies in head and neck cancerHead Neck Oncol201132521548989
   PubMedGoogle Scholar
• de BruinECMedemaJPApoptosis and non-apoptotic deaths in cancer development and treatment responseCancer Treat Rev200834873774918722718
   PubMed Web of Science ®Google Scholar
• RicciMSZongWXChemotherapeutic approaches for targeting cell death pathwaysOncologist200611434235716614230
   PubMed Web of Science ®Google Scholar
• ProskuryakovSYGabaiVLMechanisms of tumor cell necrosisCurr Pharm Des2010161566820214618
   PubMed Web of Science ®Google Scholar
• EpsteinALChenFMTaylorCRA novel method for the detection of necrotic lesions in human cancersCancer Res19884820584258483048650
   PubMed Web of Science ®Google Scholar
• MillerGKNaeveGSGaffarSAEpsteinALImmunologic and biochemical analysis of TNT-1 and TNT-2 monoclonal antibody binding to histonesHybridoma19931266896988288270
   PubMed Web of Science ®Google Scholar
• SharifJKhawliLAHuPKingSEpsteinALCharacterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumorsHybrid Hybridomics2001205–630531211839248
   PubMedGoogle Scholar
• ChenSYuLJiangCPivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancerJ Clin Oncol20052371538154715735129
   PubMed Web of Science ®Google Scholar
• McDermottDFReganMMAtkinsMBInterleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trialsClin Genitourin Cancer20065211411917026799
   PubMed Web of Science ®Google Scholar
• PhilipPAInterleukin-2 in the treatment of malignant melanomaExpert Opin Investig Drugs199873361371
   PubMedGoogle Scholar
• RosenbergSAYangJCWhiteDESteinbergSMDurability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating responseAnn Surg199822833073199742914
   PubMed Web of Science ®Google Scholar
• SmithFODowneySGKlapperJATreatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccinesClin Cancer Res200814175610561818765555
   PubMed Web of Science ®Google Scholar
• McDermottDFReganMMClarkJIRandomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinomaJ Clin Oncol200523113314115625368
   PubMed Web of Science ®Google Scholar
• LodeHNXiangRDreierTVarkiNMGilliesSDReisfeldRANatural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapyBlood1998915170617159473237
   PubMed Web of Science ®Google Scholar
• BeckerJCPancookJDGilliesSDFurukawaKReisfeldRAT cellmediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapyJ Exp Med19961835236123668642346
   PubMed Web of Science ®Google Scholar
• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
   PubMed Web of Science ®Google Scholar
• PiniAVitiFSantucciADesign and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gelJ Biol Chem19982733421769217769705314
   PubMed Web of Science ®Google Scholar
• SauerSErbaPAPetriniMExpression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patientsBlood2009113102265227419131554
   PubMed Web of Science ®Google Scholar
• BirchlerMVitiFZardiLSpiessBNeriDSelective targeting and photocoagulation of ocular angiogenesis mediated by a phage-derived human antibody fragmentNat Biotechnol1999171098498810504699
   PubMed Web of Science ®Google Scholar
• FabbriniMTrachselESoldaniPSelective occlusion of tumor blood vessels by targeted delivery of an antibody-photosensitizer conjugateInt J Cancer200611871805181316217760
   PubMed Web of Science ®Google Scholar
• NilssonFKosmehlHZardiLNeriDTargeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in miceCancer Res200161271171611212273
   PubMed Web of Science ®Google Scholar
• CarnemollaBBorsiLBalzaEEnhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrixBlood20029951659166511861281
   PubMed Web of Science ®Google Scholar
• SchliemannCPalumboAZuberbuhlerKComplete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2Blood2009113102275228319005180
   PubMed Web of Science ®Google Scholar
• WagnerKSchulzPScholzAWiedenmannBMenradAThe targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancerClin Cancer Res200814154951496018676770
   PubMed Web of Science ®Google Scholar
• SchwagerKHemmerleTAebischerDNeriDThe immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNFJ Invest Dermatol2013133375175823096716
   PubMed Web of Science ®Google Scholar
• MenradAMenssenHDED-B fibronectin as a target for antibody-based cancer treatmentsExpert Opin Ther Targets20059349150015948669
   PubMed Web of Science ®Google Scholar
• YangJCSherryRMSteinbergSMRandomized study of highdose and low-dose interleukin-2 in patients with metastatic renal cancerJ Clin Oncol200321163127313212915604
   PubMed Web of Science ®Google Scholar
• JohannsenMSpitaleriGCuriglianoGThe tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinomaEur J Cancer201046162926293520797845
   PubMed Web of Science ®Google Scholar
• EigentlerTKWeideBde BraudFA dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanomaClin Cancer Res201117247732774222028492
   PubMed Web of Science ®Google Scholar
• GarbeCPhase I/II study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in metastatic melanoma patientsVol J Clin Oncol (Meeting Abstracts)200927Suppl 1590642009
   Web of Science ®Google Scholar
• WeideBTumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with DTIC in chemotherapy-naïve stage IV melanoma patientsJ Clin Oncol (Meeting Abstracts)201028Suppl 1585552010
   Google Scholar
• BrackSSSilacciMBirchlerMNeriDTumor-targeting properties of novel antibodies specific to the large isoform of tenascin-CClin Cancer Res200612103200320816707621
   PubMed Web of Science ®Google Scholar
• MarlindJKasparMTrachselEAntibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapyClin Cancer Res200814206515652418927291
   PubMed Web of Science ®Google Scholar
• PedrettiMVerpelliCMarlindJCombination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastomaBr J Cancer2010103682783620736949
   PubMed Web of Science ®Google Scholar
• De BraudFGCataniaCMasiniCCombinations of the immunocytokine F16-IL2 with doxorubicin or with paclitaxel investigated in phase Ib studies in patients with advanced solid tumorsJ Clin Oncol (Meeting Abstracts)201028Suppl 15e13017
   Web of Science ®Google Scholar
• De BraudFGCataniaCOnofriACombination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: results from two phase Ib trialsJ Clin Oncol (Meeting Abstracts)201129Suppl abstr2595
   Web of Science ®Google Scholar
• GilliesSDReillyEBLoKMReisfeldRAAntibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cellsProc Natl Acad Sci U S A1992894142814321741398
   PubMed Web of Science ®Google Scholar
• SabzevariHGilliesSDMuellerBMPancookJDReisfeldRAA recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency miceProc Natl Acad Sci U S A19949120962696307937818
   PubMed Web of Science ®Google Scholar
• HankJASurfusJEGanJActivation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2)Clin Cancer Res1996212195119599816154
   PubMed Web of Science ®Google Scholar
• BeckerJCPancookJDGilliesSDMendelsohnJReisfeldRAEradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteinsProc Natl Acad Sci U S A1996937270227078610104
   PubMed Web of Science ®Google Scholar
• KendraKGanJRicciMPharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in miceCancer Immunol Immunother199948521922910478638
   PubMed Web of Science ®Google Scholar
• BeckerJCVarkiNGilliesSDFurukawaKReisfeldRALong-lived and transferable tumor immunity in mice after targeted interleukin-2 therapyJ Clin Invest19969812280128048981927
   PubMed Web of Science ®Google Scholar
• LodeHNXiangRVarkiNMDolmanCSGilliesSDReisfeldRATargeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrowJ Natl Cancer Inst19978921158615949362156
   PubMedGoogle Scholar
• NealZCYangJCRakhmilevichALEnhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapyClin Cancer Res200410144839484715269160
   PubMed Web of Science ®Google Scholar
• OsengaKLHankJAAlbertiniMRA phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children’s Oncology GroupClin Cancer Res20061261750175916551859
   PubMed Web of Science ®Google Scholar
• KoYJBubleyGJWeberRSafety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancerJ Immunother200427323223915076141
   PubMed Web of Science ®Google Scholar
• KingDMAlbertiniMRSchalchHPhase I clinical trial of the immunocytokine EMD 273063 in melanoma patientsJ Clin Oncol200422224463447315483010
   PubMed Web of Science ®Google Scholar
• RibasAKirkwoodJMAtkinsMBPhase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanomaJ Transl Med200976819640287
   PubMed Web of Science ®Google Scholar
• ShustermanSLondonWBGilliesSDAntitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children’s Oncology Group (COG) phase II studyJ Clin Oncol201028334969497520921469
   PubMed Web of Science ®Google Scholar
• HankJAGanJRyuHImmunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastomaClin Cancer Res200915185923593019737959
   PubMed Web of Science ®Google Scholar
• MargolinKAtkinsMBDutcherJPPhase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancerClin Cancer Res200713113312331917545537
   PubMed Web of Science ®Google Scholar
• GilliesSDLanYHettmannTA low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivityClin Cancer Res201117113673368521531812
   PubMed Web of Science ®Google Scholar
• GillessenSGnad-VogtUSGalleraniEA phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumoursEur J Cancer2013491354422918078
   PubMed Web of Science ®Google Scholar
• LutsiakMESemnaniRTDe PascalisRKashmiriSVSchlomJSabzevariHInhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamideBlood200510572862286815591121
   PubMed Web of Science ®Google Scholar
• BassKKMastrangeloMJImmunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancerCancer Immunol Immunother19984711129755873
   PubMed Web of Science ®Google Scholar
• LaurentJTouvreyCGillessenST-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion proteinJ Transl Med201311523294527
   PubMed Web of Science ®Google Scholar
• TrinchieriGInterleukin-12 and the regulation of innate resistance and adaptive immunityNat Rev Immunol20033213314612563297
   PubMed Web of Science ®Google Scholar
• AtkinsMBRobertsonMJGordonMPhase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignanciesClin Cancer Res1997334094179815699
   PubMed Web of Science ®Google Scholar
• GollobJAMierJWVeenstraKPhase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical responseClin Cancer Res2000651678169210815886
   PubMed Web of Science ®Google Scholar
• LiDShugertEGuoMBishopJSO’MalleyBWJrCombination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinomaArch Otolaryngol Head Neck Surg2001127111319132411701067
   PubMedGoogle Scholar
• ZakiMHWysockaMEverettsSESynergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphomaJ Invest Dermatol2002118236637111841558
   PubMed Web of Science ®Google Scholar
• JosephWKimCRHBilusicMarijoFirst-in-human phase I trial of NHS-IL12 in advanced solid tumorsJ Clin Oncol201230Suppl 15 abstr TPS2617
   Google Scholar
• PascheNWulhfardSPrettoFCarugatiENeriDThe antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxelClin Cancer Res201218154092410322693354
   PubMed Web of Science ®Google Scholar
• LiJHuPKhawliLAYunAEpsteinALchTNT-3/hu IL-12 fusion protein for the immunotherapy of experimental solid tumorsHybrid Hybridomics200423111015000842
   PubMedGoogle Scholar
• CarnemollaBLepriniAAllemanniGSaginatiMZardiLThe inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequenceJ Biol Chem19922673424689246921280266
   PubMed Web of Science ®Google Scholar
• MarianiGLaskuABalzaETumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implantsCancer199780Suppl 12237823849406686
   PubMed Web of Science ®Google Scholar
• MarianiGLaskuAPauAA pilot pharmacokinetic and immunoscintigraphic study with the technetium-99m-labeled monoclonal antibody BC-1 directed against oncofetal fibronectin in patients with brain tumorsCancer199780Suppl 12248424899406699
   PubMed Web of Science ®Google Scholar
• LoKMLanYLauderShuBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor modelsCancer Immunol Immunother200756444745716874486
   PubMed Web of Science ®Google Scholar
• ZouJJSchoenhautDSCarvajalDMStructure-function analysis of the p35 subunit of mouse interleukin 12J Biol Chem199527011586458717890716
   PubMed Web of Science ®Google Scholar
• RudmanSMJamesonMBMcKeageMJA phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinomaClin Cancer Res20111771998200521447719
   PubMed Web of Science ®Google Scholar
• PalladinoMABahjatFRTheodorakisEAMoldawerLLAnti-TNF-alpha therapies: the next generationNat Rev Drug Discov20032973674612951580
   PubMed Web of Science ®Google Scholar
• WatanabeNNiitsuYUmenoHToxic effect of tumor necrosis factor on tumor vasculature in miceCancer Res1988488217921833349488
   PubMed Web of Science ®Google Scholar
• FajardoLFKwanHHKowalskiJPrionasSDAllisonACDual role of tumor necrosis factor-alpha in angiogenesisAm J Pathol199214035395441372154
   PubMed Web of Science ®Google Scholar
• GammHLindemannAMertelsmannRHerrmannFPhase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancyEur J Cancer19912778568631834117
   PubMed Web of Science ®Google Scholar
• EggermontAMSchraffordt KoopsHKlausnerJMIsolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experienceAnn Surg19962246756764 discussion 764–7658968230
   PubMed Web of Science ®Google Scholar
• BonvalotSLaplancheALejeuneFLimb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?Ann Oncol20051671061106815930042
   PubMed Web of Science ®Google Scholar
• BorsiLBalzaECarnemollaBSelective targeted delivery of TNFalpha to tumor blood vesselsBlood2003102134384439212933583
   PubMed Web of Science ®Google Scholar
• de WiltJHten HagenTLde BoeckGvan TielSTde BruijnEAEggermontAMTumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusionBr J Cancer20008251000100310737379
   PubMed Web of Science ®Google Scholar
• BalzaEMortaraLSassiFTargeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic originClin Cancer Res20061282575258216638868
   PubMed Web of Science ®Google Scholar
• PapadiaFBassoVPatuzzoRIsolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanomaJ Surg Oncol2013107217317922674435
   PubMed Web of Science ®Google Scholar
• SpitaleriGBerardiRPierantoniCPhase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumoursJ Cancer Res Clin Oncol2013139344745523160853
   PubMed Web of Science ®Google Scholar
• SchwartzJEScuderiPWigginsCRudolphAHershEMA phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancyBiotherapy1989132072142642024
   PubMedGoogle Scholar
• LiuZSmythFERennerCLeeFTOosterwijkEScottAMAnti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicityCancer Immunol Immunother200251317117711941456
   PubMed Web of Science ®Google Scholar
• FriedbergJWNeubergDGribbenJGCombination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin’s lymphomaBr J Haematol2002117482883412060117
   PubMed Web of Science ®Google Scholar
• HalinCGafnerVVillaniMESynergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alphaCancer Res200363123202321012810649
   PubMed Web of Science ®Google Scholar
• HornickJLKhawliLAHuPSharifJKhannaCEpsteinALPretreatment with a monoclonal antibody/interleukin-2 fusion protein directed against DNA enhances the delivery of therapeutic molecules to solid tumorsClin Cancer Res19995151609918202
   PubMed Web of Science ®Google Scholar
• MoschettaMPrettoFBerndtAPaclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenograftsCancer Res20127271814182422392081
   PubMed Web of Science ®Google Scholar
• HoldenSALanYPardoAMWesolowskiJSGilliesSDAugmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agentsClin Cancer Res2001792862286911555604
   PubMed Web of Science ®Google Scholar
• FreyKSchliemannCSchwagerKGiavazziRJohannsenMNeriDThe immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinomaJ Urology2010184625402548
   Web of Science ®Google Scholar
• GilliesSDLanYBrunkhorstBWongWKLiYLoKMBi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancerCancer Immunol Immunother200251844946012202906
   PubMed Web of Science ®Google Scholar
• BalzaECarnemollaBMortaraLTherapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalphaInt J Cancer2010127110111019877124
   PubMed Web of Science ®Google Scholar
• ZitvogelLApetohLGhiringhelliFKroemerGImmunological aspects of cancer chemotherapyNat Rev Immunol200881597318097448
   PubMed Web of Science ®Google Scholar
• WrzesinskiCRestifoNPLess is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapyCurr Opin Immunol200517219520115766681
   PubMed Web of Science ®Google Scholar
• GribbenJGRyanDPBoyajianRUnexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapyClin Cancer Res200511124430443615958627
   PubMed Web of Science ®Google Scholar
• AntoniaSJMirzaNFrickeICombination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancerClin Cancer Res2006123 Pt 187888716467102
   PubMed Web of Science ®Google Scholar